Skip to content
Screener

Halozyme Therapeutics HALO Q4 2025 Annual earnings

Reported February 17, 2026 · After market close

Revenue$451.8MBeat by $16.1M
EPS-$0.24Miss by $2.39
Revenue estimate$435.7M
EPS estimate$2.15

Next report

Nov 2, 2026 (in a month)
Revenue estimate$482.3M
EPS estimate$2.25

Financials

Q4 2025

Income statement

See full
Revenue$451.8M+51.6%
Gross profit$373.0M+45.7%

Balance sheet

See full
Cash & equivalents$136.4M+17.8%
Total debt$2.2B+41.7%
Total equity$48.8M-86.6%
Total assets$2.5B+22.4%

Cash flow

See full
Operating cash flow$219.0M+22.7%
CapEx$1.4M-53.2%
Free cash flow$217.6M+24.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$7.91B+30.1%
Enterprise value$9.96B+32.7%
P/S5.7×-0.3×

Profitability

See full
Gross margin83.6%-0.7pp
FCF margin46.2%0.0pp

Returns & leverage

See full
Debt / equity44.6×+40.4×
Current ratio4.7×-3.1×

Segments

By product

See full
Royalties$258.0M+51.4%
Proprietary product sales$59.6M+25.9%
Bulk rHuPH20 sales$50.2M+155%
Sales-based milestones$25.0M-16.7%
Event-based development and regulatory milestones and other fees$22.5M+50.0%

By geography

See full
All other foreign$8.3M+250%

FAQ

When did Halozyme Therapeutics report Q4 2025 earnings?
Halozyme Therapeutics (HALO) reported Q4 2025 earnings on February 17, 2026 after market close.
What were Halozyme Therapeutics's Q4 2025 revenue and EPS?
Halozyme Therapeutics reported revenue of $451.8M and eps of $-0.24 for Q4 2025.
Did Halozyme Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $435.7M by $16.1M. EPS missed the consensus estimate of $2.15 by $2.39.
How did Halozyme Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 51.6% from $298.0M a year earlier.
Where can I find Halozyme Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001159036-26-000023) and the 10-K periodic report (0001159036-26-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.